ravulizumab-cwvz

Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease

The biotech company said it would initiate a Phase III trial of Ultomiris in Covid-19-related pneumonia and acute respiratory distress syndrome. The announcement comes nearly a month after it said it was exploring the use of Soliris, an older and related drug.

By Alaric DeArment

BioPharma, Legal

USPTO agrees to Amgen’s petition to review Alexion’s patents on rare disease drug

Shares of Alexion fell more than 11 percent Friday as the office instituted an inter partes review for the drug, Soliris, in the blood disorder paroxysmal nocturnal hemoglobinuria.

By Alaric DeArment

The Power of Real World Data to Study Women’s Health at Scale

Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!

By Veradigm and MedCity News

The Healthcare Payments Industry Has a Perception Problem

Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.

By Lisa Brooks, Vice President, Healthcare Partnerships

Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease

USPTO agrees to Amgen’s petition to review Alexion’s patents on rare disease drug

Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026